ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO859

Outcome of Kidney Transplantation in Patients with Polycystic Kidney Disease: A Single-Center Study

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic


  • Chen, Cheng-Hsu, Taichung Veterans General Hospital , Taichung, Taiwan
  • Yu, Tung-Min, Taichung Veterans General Hospital , Taichung, Taiwan
  • Chuang, Ya-Wen, Taichung Veterans General Hospital , Taichung, Taiwan

Renal transplant (RTx) is the best choice of life-quality of renal replacement therapy for patients with end-stage renal disease (ESRD). Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder and common cause of ESRD. Different from other causes of ESRD, ADPKD patients need more delicate pre-RTx evaluation for intracranial aneurisms, cardiac manifestation, and complications of liver and renal cysts. The outcome of RTx with ADPKD is still unknown in Taiwan.


We retrieved our 1327 RTx recipients with 1382 times (two recipients with 3 times, 48 recipients with 2 times) of RTx in the past 35 years. There were 41 recipients with ADPKD. This study evaluated the demographics, outcomes, and complications of RTx in patients with ADPKD compared with other nephropathies.


The mean recipient age at first RTx was 42.9 ± 12.6 years, however, the ADPKD group (52.5 ± 10.1 yrs) was elder than other group (42.7 ± 12.7 yrs, P = 0.001). The gender of RTx recipients was female 586 (44.2%) and male 741 (55.8%), though, ADPKD group had higher male gender (28, 68.3%) than other group (713, 55.4%) without statistically significance (P = 0.245). Interestingly, the new onset diabetes after transplant (NODAT) was higher in ADPKD group (21, 51.2%) than other group (326, 25.3%; P = 0.005), and more malignancy (18; 43.9% vs. 360; 28.0%; P = 0.041). The patient survival was inferior in ADPKD group (38.9% vs. 70.3%; P = 0.018).


Further studies with multiple centers and greater numbers of patients are needed to compare more precisely the complications and results of transplant between patients with ADPKD and other recipients in Taiwan.